Novartis to acquire SNV4818 from Synnovation [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones to acquire Synnovation Therapeutics' wholly owned subsidiary Pikavation Therapeutics, which holds SNV4818 and related programmes. Through the acquisition, Novartis plans to explore a new method to treat patients with hormone receptor-positive (HR+) / human epidermal growth factor receptor 2 (HER2)- breast cancer and other solid tumour indications. SNV4818 is an oral drug and is presently being assessed in an ongoing Phase I/II trial for breast cancer and other advanced solid tumours. The programme aligns with Novartis' aim to develop treatments for breast cancer and complements existing cyclin-dependent kinase (CDK) inhibitors and endocrine therapies as part of potential combination strategies. Preclinical data has demonstrated strong activity against common Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. Clinical evaluation is progressing. The deal is
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis Strikes $3B Oncology Deal for Breast Cancer Asset [Yahoo! Finance]Yahoo! Finance
- Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance]Yahoo! Finance
- Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline [Yahoo! Finance]Yahoo! Finance
- Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Ka Inhibitor Program [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website